Free 24-hour delivery over £60 · Same-day despatchOrder before 2pm - same-day despatch · Free 24-hour delivery over £60
Research use only
· 6 min read
A Certificate of Analysis records the analytical tests run on a single research peptide lot. This guide explains what each field means: how HPLC purity is calculated, how mass spectrometry confirms identity, why the two methods are paired, what a batch number ties back to, and why an independently issued certificate carries more verification weight than an in-house claim. Strictly research-use framing throughout.
| Document | Certificate of Analysis (COA) for one research peptide lot |
|---|---|
| Purity method | Reverse-phase HPLC, area-normalisation percentage |
| Identity method | Mass spectrometry (ESI-MS or MALDI-TOF), observed vs theoretical mass |
| Common UV wavelength | 214 nm (the peptide bond absorbs strongly here) |
| Traceability | Batch / lot number tying the certificate to the physical material |
| Common research expectation | >=98-99 percent HPLC (a convention, not a pharmacopoeial mandate) |
A Certificate of Analysis (COA) is the formal quality-control document that accompanies a research peptide batch. It records the analytical tests run on that specific lot, the methods used, the measured numerical results, and the acceptance criteria the lab applied. A complete COA reports actual numerical results, not merely a pass or fail statement, and it names the test methods used. A line that reads "purity: pass" with no figure and no method tells you far less than one that reads "purity: 98.4 percent by RP-HPLC." Everything below is framed as laboratory verification of a reagent's documented chemical identity and quality. None of it concerns dosing, administration, or any human or animal use; the point of a COA in a research setting is reproducibility, meaning confidence that bench results reflect the intended compound and not its impurities. Every Kovalabs research-peptide batch ships with a Certificate of Analysis, and the documents are archived by lot.
Reverse-phase HPLC (RP-HPLC) is the principal method used to assess the chromatographic purity of a synthetic peptide. Purity is calculated by area normalisation: the area of the target peptide peak divided by the total area of all detected peaks, expressed as a percentage. A 98 percent HPLC result means the target species accounts for 98 percent of the total UV-absorbing material detected, with the remaining 2 percent being other detectable species, or impurities. Peptide HPLC commonly uses UV detection at 214 nm because the peptide (amide) bond itself absorbs strongly in the 214 to 220 nm region. Kuipers and Gruppen (J Agric Food Chem 2007, DOI 10.1021/jf070337l) report a molar extinction coefficient of 923 M-1 cm-1 for the peptide bond at 214 nm. Because every peptide contains amide bonds, monitoring at 214 nm detects essentially all peptide species in the sample, which is what makes the area-normalisation figure meaningful in the first place. Two caveats keep the number honest. First, HPLC purity is a percentage of detected species and an estimate, not an absolute measure of identity: it confirms only that the dominant detected species is highly abundant relative to the others, not that the dominant species is the intended molecule. Second, impurities below the chromatographic detection limit do not appear on the trace at all, so the reported figure is a floor on quality rather than a perfect census.
Under identical chromatographic conditions a given peptide elutes at the same time, so HPLC retention time acts as a reproducible fingerprint. A main peak whose retention time matches the expected or reference-standard value supports identity, though it does not by itself prove it. The Sigma-Aldrich (Merck) technical note on LC/MS peptide standards describes this system-suitability and retention-time use directly. The known limitation is co-elution: two species that share the same retention time appear as a single peak and cannot be told apart by HPLC alone. Closing that gap is the job of the mass spectrometry section of the certificate.
Mass spectrometry, commonly ESI-MS or MALDI-TOF, confirms molecular identity by comparing the observed (measured) molecular weight against the theoretical molecular weight calculated from the intended amino acid sequence. A close match between observed and theoretical mass is the core identity check on a COA. ESI typically generates multiply charged ions that require deconvolution to a neutral mass, whereas MALDI predominantly produces singly charged ions; Strupat (Methods Enzymol 2005, DOI 10.1016/S0076-6879(05)05001-9) sets out both approaches. Mass spectrometry has its own blind spot, which is precisely why it is paired with high-resolution chromatography. Isobaric impurities, such as aspartate and isoaspartate isomers, share the same mass as the target peptide, so they cannot be distinguished by mass alone and need adequate chromatographic separation to be detected. Deamidation produces only a small mass increase of about 1 Da, which low-resolution instruments can also miss. That mutual coverage is why both methods appear together on a rigorous certificate.
HPLC and MS are complementary, or orthogonal. HPLC verifies that the sample is predominantly one component, while MS confirms that the component has the expected molecular mass. Neither alone is sufficient. A certificate that includes both an HPLC chromatogram and MS data gives substantially more analytical confidence than an HPLC purity figure on its own. It is also worth separating two different numbers that both get called "purity." The single HPLC area-normalisation percentage on most certificates is one thing. The value-assigned purity of a formal reference standard is another and stricter figure: it is often established by a mass-balance approach, where every detectable impurity (peptide-related impurities, counter ion, water, residual solvents) is quantified and subtracted from 100 percent. A USP-authored review of reference standards for synthetic peptide therapeutics (PMC10338602) describes this mass-balance assignment alongside orthogonal identity techniques, including HPLC retention time, MS with MS/MS sequence confirmation, NMR, amino acid analysis and chiral testing. Do not read a mass-balance figure and a single HPLC percentage as the same measurement.
The impurities that make up the small remaining percentage on a purity line mostly come from the synthesis itself. Common peptide-related impurities include deletion (truncated) sequences from incomplete coupling, protection and deprotection adducts, dimeric and oligomeric species from aggregation, and oxidised side chains. A higher purity figure corresponds to fewer of these synthesis by-products in the material. For synthetic peptides more broadly, USP General Chapter <1503> Quality Attributes of Synthetic Peptide Drug Substances (official 1 August 2021) sets out the attributes and test methods considered, including identity, content and assay, purity and peptide-related impurities, residual solvents, counter-ion content, water content, and microbial and endotoxin limits. The named analytical methods include HPLC, mass spectrometry, LC-MS/MS, amino acid analysis, NMR and peptide mapping. The chapter exists because synthetic peptides were excluded from many earlier small-molecule specification guidances. One thing it does not do is set a single universal numeric purity threshold; the commonly quoted >=98-99 percent figure is a research convention, not a pharmacopoeial mandate, and impurity limits are product-specific.
A batch (lot) number identifies one specific production run: every unit from the same synthesis, purification and QC cycle carries the same identifier, and it is the traceable link between the material in hand and the exact tests on the certificate. Because conditions vary slightly each run, no two batches are identical, so each COA documents testing on that unique lot rather than representative or historical data. A certificate with no traceable lot number cannot be tied to the material and is therefore of little value. Who performed the testing is the other axis. An independent third-party lab sits outside the manufacturer's chain of control, with no financial interest in whether a batch passes or fails. Manufacturer-only, in-house testing carries an inherent conflict of interest because the entity producing the material also reports its quality results. That is why an independently issued certificate carries more verification weight than an in-house claim, and why it is worth confirming that an external lab actually ran the analysis rather than accepting a label that only states "third-party tested."
A researcher confirming that the material in hand matches its documented identity can work through four steps. First, confirm the COA batch or lot number matches the label on the vial. Second, read the HPLC purity figure and check the main-peak retention time against the expected or reference value. Third, confirm the MS section shows an observed molecular weight matching the theoretical mass for that peptide. Fourth, note which lab performed the testing, independent or in-house, and that the methods are stated. The field-by-field table above maps each line of a typical certificate to what it actually tells you. The whole chain only holds if the lot number on the vial ties back to the certificate; break that link and the rest of the document is describing some other material. You can review Kovalabs batch certificates on the Certificate of Analysis archive, read the full research-use-only terms, or browse the catalogue to see how documentation accompanies each lot.
This guide is provided for laboratory and research information only. Kovalabs supplies research peptides and research chemicals to qualified researchers strictly for in-vitro and laboratory research use. They are not medicines, are not a preparation for any use in humans or animals, and nothing here describes or implies dosing, administration, reconstitution for injection, diagnosis, treatment, or any therapeutic use. Reading a Certificate of Analysis is a question of verifying a reagent's documented chemical identity and quality for reproducible bench work, nothing more. Full terms are set out in the research-use-only terms.
| COA field | What it tells you |
|---|---|
| Product / peptide name and CAS | States which compound the lot was tested as |
| Batch / lot number | Ties the certificate to the physical material and its full test history |
| Purity (RP-HPLC, percent) | Proportion of detected species that is the target peptide, by peak-area normalisation |
| HPLC retention time | Chromatographic fingerprint supporting identity under defined conditions |
| Mass spectrometry (observed vs theoretical MW) | Confirms the molecule has the expected mass (identity) |
| Test methods (RP-HPLC, ESI-MS / MALDI etc.) | The documented, repeatable procedures used |
| Testing laboratory (independent vs in-house) | Who verified the result and whether a conflict of interest exists |
| Date of analysis / storage conditions | When the result applies and the laboratory storage conditions recorded for the lot |
It means the target peptide peak accounts for 98 percent of the total UV-absorbing material the chromatograph detected, calculated by area normalisation (the area of the target peak divided by the total area of all detected peaks). The remaining 2 percent is other detectable species. The figure estimates how dominant the main species is relative to other detected species; it does not on its own prove that the dominant species is the intended molecule, which is why HPLC is paired with mass spectrometry for identity.
They are orthogonal methods. HPLC verifies the sample is predominantly one component (purity), while mass spectrometry confirms that component has the expected molecular mass (identity). Neither is sufficient alone: HPLC cannot distinguish two species that co-elute at the same retention time, and mass spectrometry cannot resolve isobaric impurities, such as aspartate and isoaspartate isomers, that share the same mass as the target and require chromatographic separation to be seen. A certificate carrying both gives substantially more analytical confidence than a purity figure alone.
No universal numeric threshold is mandated. The >=98-99 percent figure quoted by many suppliers is an industry and research convention, not a pharmacopoeial requirement. USP General Chapter <1503> describes the quality attributes and analytical methods considered for synthetic peptide drug substances, but impurity limits are product-specific rather than a single fixed percentage. Treat the percentage as a common expectation, and read it alongside the method, the identity data and the lab that produced it.
An independent third-party lab sits outside the manufacturer's chain of control and has no financial interest in whether a batch passes. Manufacturer-only testing carries an inherent conflict of interest because the entity producing the material also reports its quality results. An independently issued certificate therefore carries more verification weight, and it is worth confirming that an external lab actually performed the analysis rather than accepting a label that merely states third-party tested.
Confirm the batch or lot number on the certificate matches the label on the vial; read the HPLC purity figure and check the main-peak retention time against the expected or reference value; confirm the mass spectrometry section shows an observed molecular weight matching the theoretical mass for that peptide; and note which lab performed the testing and that the methods are stated. The chain only holds if the lot number on the vial ties back to the certificate.
A batch or lot number identifies one specific production run, and every unit from that synthesis, purification and QC cycle carries the same identifier. Because raw materials, synthesis conditions and purification efficiency vary slightly each run, no two batches are identical, so each COA documents testing on that unique lot rather than representative or historical data. A certificate with no traceable lot number cannot be tied to the material and is of little value.